Abstract
Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in various physiological and pathological conditions, including embryonic development, wound repair, inflammation, and tumor growth. The 1980s saw for the first time the identification, purification, and sequencing of the two prototypic heparin-binding angiogenic fibroblast growth factors (FGF) 1 and 2. Since then, 22 structurally-related members of the FGF family and differenent classes of FGF receptors have been identified. Several experimental evidences point to a role for various FGFs in the neovascularization process that takes place in inflammation, angioproliferative diseases, and tumor growth. Thus, the FGF/FGF receptor system represents a target for the development of antiangiogenic therapies. Purpose of this review is to summarize the different modalities that have been approached to impair the proangiogenic activity of the FGF/FGF receptor system and discuss their possible therapeutic implications.
Keywords: Angiogenesis, endothelium, FGF, FGF receptors, inhibitors
Current Pharmaceutical Design
Title: Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Volume: 13 Issue: 20
Author(s): M. Rusnati and M. Presta
Affiliation:
Keywords: Angiogenesis, endothelium, FGF, FGF receptors, inhibitors
Abstract: Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in various physiological and pathological conditions, including embryonic development, wound repair, inflammation, and tumor growth. The 1980s saw for the first time the identification, purification, and sequencing of the two prototypic heparin-binding angiogenic fibroblast growth factors (FGF) 1 and 2. Since then, 22 structurally-related members of the FGF family and differenent classes of FGF receptors have been identified. Several experimental evidences point to a role for various FGFs in the neovascularization process that takes place in inflammation, angioproliferative diseases, and tumor growth. Thus, the FGF/FGF receptor system represents a target for the development of antiangiogenic therapies. Purpose of this review is to summarize the different modalities that have been approached to impair the proangiogenic activity of the FGF/FGF receptor system and discuss their possible therapeutic implications.
Export Options
About this article
Cite this article as:
M. Rusnati and M. Presta , Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies, Current Pharmaceutical Design 2007; 13 (20) . https://dx.doi.org/10.2174/138161207781039689
DOI https://dx.doi.org/10.2174/138161207781039689 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanocarriers as Prospective Approach in Effective Management of Acne Vulgaris
Micro and Nanosystems Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors
Current Pharmaceutical Design The FRK / RAK-SHB Signaling Cascade: A Versatile Signal- Transduction Pathway that Regulates Cell Survival, Differentiation and Proliferation
Current Molecular Medicine A Review of Animal and Human Studies for Management of Benign Prostatic Hyperplasia with Natural Products: Perspective of New Pharmacological Agents
Inflammation & Allergy - Drug Targets (Discontinued) Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Short Peptide Modules for Enhancing Intestinal Barrier Function
Current Pharmaceutical Design The Hedgehog Signaling Pathway as a Target for Anticancer Drug Discovery
Current Topics in Medicinal Chemistry Cytosine Methyltransferases as Tumor Markers
Current Genomics Disaggregating Chaperones: An Unfolding Story
Current Protein & Peptide Science Synthesis and Anti-tumor Activities of Novel Phenyl Substituted Suberoylanilide Hydroxamic Acid Derivatives Against Human Cancer Cells
Medicinal Chemistry The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension
Vascular Disease Prevention (Discontinued) The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Roles of Perilipins in Diseases and Cancers
Current Genomics Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued)